|
1.
|
Bonner JA, Harari PM, Giralt J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Fu KK, Pajak TF, Trotti A, et al: A
Radiation Therapy Oncology Group (RTOG) phase III randomized study
to compare hyper-fractionation and two variants of accelerated
fractionation to standard fractionation radiotherapy for head and
neck squamous cell carcinomas: first report of RTOG 9003. Int J
Radiat Oncol Biol Phys. 48:7–16. 2000. View Article : Google Scholar
|
|
3.
|
Posner MR, Hershock DM, Blajman CR, et al:
Cisplatin and fluorouracil alone or with docetaxel in head and neck
cancer. N Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Shiboski CH, Schmidt BL and Jordan RC:
Tongue and tonsil carcinoma: increasing trends in the U.S.
population ages 20–44 years. Cancer. 103:1843–1849. 2005.PubMed/NCBI
|
|
5.
|
Bourhis J, Overgaard J, Audry H, et al:
Hyperfractionated or accelerated radiotherapy in head and neck
cancer: a meta-analysis. Lancet. 368:843–854. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Denis F, Garaud P, Bardet E, et al: Final
results of the 94-01 French Head and Neck Oncology and Radiotherapy
Group randomized trial comparing radiotherapy alone with
concomitant radiochemotherapy in advanced-stage oropharynx
carcinoma. J Clin Oncol. 22:69–76. 2004. View Article : Google Scholar
|
|
7.
|
Garden AS, Harris J, Vokes EE, et al:
Preliminary results of Radiation Therapy Oncology Group 97-03: a
randomized phase II trial of concurrent radiation and chemotherapy
for advanced squamous cell carcinomas of the head and neck. J Clin
Oncol. 22:2856–2864. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kao J, Lavaf A, Teng MS, Huang D and
Genden EM: Adjuvant radiotherapy and survival for patients with
node-positive head and neck cancer: an analysis by primary site and
nodal stage. Int J Radiat Oncol Biol Phys. 71:362–370. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Lee NY, de Arruda FF, Puri DR, et al: A
comparison of intensity-modulated radiation therapy and concomitant
boost radiotherapy in the setting of concurrent chemotherapy for
locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol
Phys. 66:966–974. 2006. View Article : Google Scholar
|
|
10.
|
Mell LK, Dignam JJ, Salama JK, et al:
Predictors of competing mortality in advanced head and neck cancer.
J Clin Oncol. 28:15–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Argiris A, Brockstein BE, Haraf DJ, et al:
Competing causes of death and second primary tumors in patients
with locoregionally advanced head and neck cancer treated with
chemoradiotherapy. Clin Cancer Res. 10:1956–1962. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Vu HL, Sikora AG, Fu S and Kao J:
HPV-induced oropharyngeal cancer, immune response and response to
therapy. Cancer Lett. 288:149–155. 2009.PubMed/NCBI
|
|
13.
|
Gillison ML: Human papillomavirus and
prognosis of oropharyngeal squamous cell carcinoma: implications
for clinical research in head and neck cancers. J Clin Oncol.
24:5623–5625. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Licitra L, Perrone F, Bossi P, et al:
High-risk human papillomavirus affects prognosis in patients with
surgically treated oropharyngeal squamous cell carcinoma. J Clin
Oncol. 24:5630–5636. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
D’Souza G, Kreimer AR, Viscidi R, et al:
Case-control study of human papillomavirus and oropharyngeal
cancer. N Engl J Med. 356:1944–1956. 2007.PubMed/NCBI
|
|
16.
|
Lavaf A, Genden EM, Cesaretti JA, Packer S
and Kao J: Adjuvant radiotherapy improves overall survival for
patients with lymph node-positive head and neck squamous cell
carcinoma. Cancer. 112:535–543. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Coviello V and Boffess M: Cumulative
incidence estimation in the presence of competing risks. Stata J.
4:103–112. 2004.
|
|
18.
|
Kim HT: Cumulative incidence in competing
risks data and competing risks regression analysis. Clin Cancer
Res. 13:559–565. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Haddad RI and Shin DM: Recent advances in
head and neck cancer. N Engl J Med. 359:1143–1154. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Settle K, Posner MR, Schumaker LM, et al:
Racial survival disparity in head and neck cancer results from low
prevalence of human papillomavirus infection in black oropharyngeal
cancer patients. Cancer Prev Res (Phila Pa). 2:776–781. 2009.
View Article : Google Scholar
|
|
21.
|
Genden EM, Rinaldo A, Shaha AR, et al:
Treatment considerations for head and neck cancer in the elderly. J
Laryngol Otol. 119:169–174. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Pignon JP, le Maitre A, Maillard E and
Bourhis J: Meta-analysis of chemotherapy in head and neck cancer
(MACH-NC): an update on 93 randomised trials and 17,346 patients.
Radiother Oncol. 92:4–14. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kao J, Sikora AT and Fu S: Dual EGFR and
COX-2 inhibition as a novel approach to targeting head and neck
squamous cell carcinoma. Curr Cancer Drug Targets. 9:931–937. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Greene FL; American Joint Committee on
Cancer. and American Cancer Society: AJCC cancer staging manual.
Springer; New York: 2002, View Article : Google Scholar
|
|
25.
|
Pfister DG, Su YB, Kraus DH, et al:
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy
for locoregionally advanced, squamous cell head and neck cancer: a
pilot phase II study of a new combined-modality paradigm. J Clin
Oncol. 24:1072–1078. 2006. View Article : Google Scholar
|
|
26.
|
Salama JK, Stenson KM, Kistner EO, et al:
Induction chemotherapy and concurrent chemoradiotherapy for
locoregionally advanced head and neck cancer: a multi-institutional
phase II trial investigating three radiotherapy dose levels. Ann
Oncol. 19:1787–1794. 2008. View Article : Google Scholar
|
|
27.
|
Duffy SA, Ronis DL, McLean S, et al:
Pretreatment health behaviors predict survival among patients with
head and neck squamous cell carcinoma. J Clin Oncol. 27:1969–1975.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Khuri FR, Lee JJ, Lippman SM, et al:
Randomized phase III trial of low-dose isotretinoin for prevention
of second primary tumors in stage I and II head and neck cancer
patients. J Natl Cancer Inst. 98:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Pearson TA, Blair SN, Daniels SR, et al:
AHA guidelines for primary prevention of cardiovascular disease and
stroke: 2002 update: consensus panel guide to comprehensive risk
reduction for adult patients without coronary or other
atherosclerotic vascular diseases. American Heart Association
Science Advisory and Coordinating Committee. Circulation.
106:388–391. 2002.
|
